Bruker Co. (NASDAQ:BRKR) Stock Position Increased by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS boosted its position in Bruker Co. (NASDAQ:BRKR) by 74.7% during the 4th quarter, HoldingsChannel reports. The firm owned 145,000 shares of the medical research company’s stock after buying an additional 62,000 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Bruker were worth $8,500,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC raised its position in shares of Bruker by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company’s stock worth $779,000 after buying an additional 177 shares in the last quarter. CIBC Asset Management Inc raised its position in shares of Bruker by 5.6% during the 4th quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company’s stock worth $248,000 after buying an additional 223 shares in the last quarter. UMB Bank n.a. raised its position in shares of Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock worth $53,000 after buying an additional 248 shares in the last quarter. Blue Trust Inc. raised its position in shares of Bruker by 13.5% during the 4th quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company’s stock worth $127,000 after buying an additional 257 shares in the last quarter. Finally, US Bancorp DE raised its position in shares of Bruker by 2.1% during the 3rd quarter. US Bancorp DE now owns 12,700 shares of the medical research company’s stock worth $877,000 after buying an additional 260 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BRKR has been the topic of a number of recent analyst reports. Guggenheim restated a “buy” rating on shares of Bruker in a research report on Friday, January 17th. TD Cowen lowered their price objective on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective on the stock in a research note on Thursday, December 5th. UBS Group initiated coverage on shares of Bruker in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price objective on the stock. Finally, Barclays lowered their price objective on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.50.

Bruker Stock Performance

Bruker stock opened at $50.75 on Wednesday. The firm’s 50 day simple moving average is $57.14 and its 200-day simple moving average is $60.24. Bruker Co. has a fifty-two week low of $48.07 and a fifty-two week high of $94.86. The company has a market cap of $7.69 billion, a P/E ratio of 24.40, a price-to-earnings-growth ratio of 3.81 and a beta of 1.16. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 9.41% and a return on equity of 21.52%. As a group, equities research analysts predict that Bruker Co. will post 2.4 EPS for the current year.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.